Advanced
Products
Solutions
Partners
Resources
Company
Toggle menu
Home
/
Eutilex
Eutilex
Overview
Locations
Financials
Operating Metrics
Human Capital
Key People
Competitors
Supplier Risk
Eutilex
Revenue
₩73.5 M
FY, 2021
Market Capitalization
₩55.6 B
2022-08-19
Eutilex Summary
Company summary
Overview
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
Type
Public
Status
Active
Founded
2015
HQ
KR
|
view all locations
Website
http://eutilex.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100
|
View all ESG data
Sectors
Healthcare
biotech
oncology
therapy
Homepage
Key people
Byoung S. Kwon,
CEO
Soo Young Choi,
COO
Edwin E. Kwon,
CFO
Jeonghoon Han,
CBO
and 1 others
Locations
View all
1 location detected
Seoul
HQ
Korea (Republic of)
25 Gasan digital 1-ro, Geumcheon-gu
Report incorrect company information
Eutilex Financials
Summary financials
Revenue (Q1, 2022)
₩22.3M
Gross profit (Q1, 2022)
₩23.2M
Net income (Q1, 2022)
(₩8.5B)
Cash (Q1, 2022)
₩51.4B
EBIT (Q1, 2022)
(₩8.6B)
Enterprise value
$29.3B
Competitors and similar companies
ImmPACT-Bio
Healthcare - Private
Anaveon
Healthcare - Private
Abcuro
Healthcare - Private
NKMax
Healthcare - Private
Compare competitors
News
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
Jan 27, 2021
Report incorrect company information
Footer menu
Contact us
Facebook
Twitter
LinkedIn
Products
Intelligence Suite
Supplier Intelligence Platform
Craft Intelligence Portal
Craft API
Craft for Teams
Supplier Intelligence Platform
Craft Alerts
Craft N-Tier Mapping
Craft Risk Hub
Chrome extension
Solutions
Supplier Intelligence
Sales Intelligence
Aerospace and Defense
Resources
Resource center
Blog
Press
Company
About
Careers
Terms of Service
Privacy Policy
© Craft.co 2023
Share price data provided by IEX
Company directory
Search directory
Back
to top